股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊 ...

NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s)(Note 1) , EuroEyes International Eye Clinic Limited (the "Company") - Notification of publication of 2025 Interim Report (the "Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at ir.euroeyes.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company stro ...

NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. EuroEyes International Eye Clinic Limited (the "Company") – Notice of publication of 2025 Interim Report ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at ir.euroeyes.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends ...

EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） Stock code 股份代號: 1846 Interim Report 中期報告 2025 目錄 德視佳國際眼科有限公司 | 2025年中期報告 1 2 公司資料 4 主要財務摘要 6 獨立核數師報告 7 中期簡明綜合財務狀況表 9 中期簡明綜合全面收益表 11 中期簡明綜合權益變動表 13 中期簡明綜合現金流量表 14 簡明綜合財務資料附註 44 管理層討論及分析 53 其他資料 公司資料 董事會 執行董事 Jørn Slot Jørgensen醫生 （主席兼行政總裁） Markus Braun博士 （自2025年9月14日起辭任執行董事及首席財務官） Jannik Jonas Slot Jørgensen先生 Dan Zoltan Reinstein 教授 非執行董事 Marcus Huascar Bracklo先生 （自2025年9月14日起調 ...

此次收购使德视佳能够立即在瑞士主要城市建立业务据点，并巩固其在伦敦市场的地位。董事会认为此 次收购是集团向瑞士市场进行战略扩张并巩固英国市场地位的重要举措，预计将对集团的长期增长做出 积极贡献。 （文章来源：证券时报网） 德视佳公告，其全资附属公司EuroEyes Swiss将以1201万瑞士法郎（约合1.17亿港元）收购Betterview Swiss在瑞士的七间屈光手术诊所、一间屈光手术治疗手术室及相关总部资产。同时，全资附属公司 EuroEyes UK将以20万瑞士法郎（约合194.886万港元）收购Betterview UK在英国的眼科服务业务相关资 产。 ...

Group 1 - The company announced the acquisition of Swiss and UK assets from Betterview, with a total consideration of approximately 12.01 million Swiss francs (about 1.17 billion HKD) for Swiss assets and 200,000 Swiss francs (approximately 18,442 GBP and 1.94886 million HKD) for UK assets [1][2] - The Swiss assets include seven refractive surgery clinics located in major cities such as Zurich, Bern, and Geneva, along with a surgical room and various headquarters assets, including contracts, customer data, and medical equipment [2][3] - The acquisition is expected to strategically expand the company's presence in the important European market of Switzerland and strengthen its position in the UK, contributing positively to long-term growth [3] Group 2 - The company primarily engages in refractive surgery services, and the acquired clinics have generated recurring revenue and possess a solid customer base [3] - The board believes that the terms of the acquisition are fair and reasonable, aligning with the overall interests of the company and its shareholders [3]

Group 1 - EuroEyes Swiss, a wholly-owned subsidiary of the company, has entered into an agreement to acquire Swiss assets from Betterview Swiss for a total consideration of 12.01 million Swiss Francs (approximately 117 million HKD) [1] - The assets to be acquired include seven refractive surgery medical clinics located in Zurich, Bern, Lucerne, St. Gallen, Lugano, Lausanne, and Geneva, as well as a refractive surgery operating room in Zurich [1] - The acquisition also includes various headquarters assets such as commercial contracts, customer contracts, employment contracts, leasing contracts, and past patient agreements (excluding those retained by Betterview Swiss) [1] Group 2 - EuroEyes UK, another wholly-owned subsidiary of the company, has signed an agreement to acquire UK assets from Betterview UK for a total consideration of 200,000 Swiss Francs (approximately 184,400 GBP and 1.949 million HKD) [2] - The assets to be acquired consist of properties, assets, and rights used in Betterview UK's ophthalmic services business, which operates under the names "Betterview" or "Betterview Britain" [2] - The UK business includes services such as laser treatment and refractive surgery, but excludes certain business debts, cash on hand or in banks, and any recoverable tax amounts related to the UK business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 須予披露的交易 透過附屬公司收購瑞士及英國資產 收購事項 董事會欣然宣佈，於2025年9月2日（交易時段後），EuroEyes Swiss（作為買 方）、本公司（作為擔保人）與Betterview Swiss（作為賣方）訂立瑞士協議，據此 EuroEyes Swiss同意購買，及Betterview Swiss同意出售瑞士資產，瑞士代價總 額為12,010,000瑞士法郎（相當於約117,029,043港元）。 董事會亦欣然宣佈，於2025年9月2日（交易時段後），EuroEyes UK（作為買方） 與Betterview UK（作為賣方）訂立英國協議，據此EuroEyes UK同意購買，及 Betterview UK同意出售英國資產，英國代 ...

公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊股本總額： USD 10,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證 ...

Core Viewpoint - 德视佳 (01846) reported a revenue of HKD 377 million for the six months ending June 30, 2025, representing a year-on-year increase of 2.4% [1] - The company's profit for the same period was HKD 40.405 million, reflecting a year-on-year decrease of 12.7% [1] - Basic earnings per share stood at HKD 0.11999 [1] Financial Performance - Revenue for the period reached HKD 377 million, up 2.4% compared to the previous year [1] - Profit decreased to HKD 40.405 million, down 12.7% year-on-year [1] - Basic earnings per share were reported at HKD 0.11999 [1]